ATRX

Across TCGA pan-cancer cohorts, ATRX Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ATRX data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ATRX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATRX expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

THYM, UCEC, and MESO are the cancer types where ATRX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.673	0.978	<.001	39	view →
UCEC	OS	Median	II,III,IV	0.892	0.308	.002	36	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LIHC	DFS	Median	III,IV	0.081	0.360	.020	9	view →
STAD	DFS	Median	All	1.000	0.645	.013	7	view →
BLCA	OS	Median	All	0.213	0.691	.018	6	view →
LGG	OS	Median	All	0.943	0.884	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ATRX–THYM (OS)

Open the THYM breakdown →